Oseltamivir reduces duration and complications of influenza
the ONA take:
According to a new study published in the journal The Lancet, researchers at the University of Michigan, the University of Alabama, and the London School of Hygiene and Tropical Medicine have found that oseltamivir, a neuraminidase inhibitor, decreases the duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
For the meta-analysis, researchers identified clinical trials conducted between 1997 and 2001. The studies included over 4,300 patients with more than half being treated with oseltamivir for influenza.
Results showed that when patients took oseltamivir 75mg twice daily within 36 hours of developing at least two flu symptoms, oseltamivir decreased the duration of the flu by 21%.
Patients who took oseltamivir experienced symptom alleviation at 98 hours versus 123 hours for those who took placebo.
In addition, researchers found that 4.9% of those who took oseltamivir had respiratory complications compared with 8.7% of those who took placebo. Oseltamivir was also shown to reduce hospital admissions by 63%. In regard to safety, oseltamivir increased nausea and vomiting, but did not cause more neurological or psychological disorders than placebo.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|